Max S Cynader

Title: Max S Cynader: Innovator in Neuroprotective Peptides

Introduction

Max S Cynader is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of neuroprotective peptides, holding a total of 3 patents. His work focuses on innovative methods for treating neurological disorders and enhancing our understanding of neurological functions.

Latest Patents

Cynader's latest patents include neuroprotective peptides that inhibit the interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (zD17) and c-jun N-terminal kinase (JNK). The isolated polypeptides disclosed in his patents comprise at least 90% identity to specific sequences, which are designed to inhibit this critical interaction. Additionally, these polypeptides may be conjugated to delivery and targeting moieties, such as the cell-membrane transduction domain of the HIV-1 Tat protein. His inventions also encompass methods for treating diseases associated with cytotoxicity or excitotoxicity, as well as processes for preparing and delivering selected nucleic acid sequences to cells.

Career Highlights

Max S Cynader is affiliated with the University of British Columbia, where he continues to advance research in his field. His innovative approaches have garnered attention and recognition within the scientific community.

Collaborations

Cynader has collaborated with notable colleagues, including Francis Tufaro and Pierre Zakarauskas, contributing to the advancement of research in neuroprotective therapies.

Conclusion

Max S Cynader's work in neuroprotective peptides represents a significant advancement in the treatment of neurological disorders. His innovative patents and collaborations highlight his commitment to improving health outcomes through scientific research.